Gilead Sciences (NASDAQ:GILD) Issues FY 2025 Earnings Guidance

Key Points

• Gilead Sciences has updated its FY 2025 earnings guidance, projecting earnings per share between $7.950 and $8.250, slightly below the consensus estimate of $7.962.
• The company expects revenue in the range of $28.3 billion to $28.7 billion, aligning close to the consensus revenue estimate of $28.7 billion.
• Recent analyst ratings have varied, with Oppenheimer lowering its price target to $125.00, while Needham upgraded its rating to "buy" with a target price of $133.00.

Gilead Sciences (NASDAQ:GILD - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 7.950-8.250 for the period, compared to the consensus earnings per share estimate of 7.962. The company issued revenue guidance of $28.3 billion-$28.7 billion, compared to the consensus revenue estimate of $28.7 billion.

Analyst Ratings Changes

A number of analysts recently weighed in on GILD shares. Oppenheimer decreased their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price on the stock. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a report on Friday, July 25th. Finally, Morgan Stanley boosted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Eight research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $112.36.

Gilead Sciences Stock Performance

NASDAQ GILD remained flat at $110.28 during mid-day trading on Thursday. 9,177,248 shares of the company were exchanged, compared to its average volume of 8,393,055. The firm has a market capitalization of $137.18 billion, a PE ratio of 23.22, a PEG ratio of 0.71 and a beta of 0.33. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. Gilead Sciences has a 1 year low of $72.43 and a 1 year high of $119.96. The firm's fifty day simple moving average is $110.76 and its two-hundred day simple moving average is $107.12.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.02. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. During the same quarter in the previous year, the business earned $2.01 EPS. On average, analysts anticipate that Gilead Sciences will post 7.95 EPS for the current year.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the transaction, the chief executive officer owned 605,725 shares of the company's stock, valued at $69,016,306.50. This trade represents a 1.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total transaction of $277,575.00. Following the completion of the transaction, the chief financial officer directly owned 162,610 shares of the company's stock, valued at $18,054,588.30. This trade represents a 1.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock worth $8,984,175 in the last ninety days. 0.27% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

A hedge fund recently bought a new stake in Gilead Sciences stock. Bison Wealth LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 2,328 shares of the biopharmaceutical company's stock, valued at approximately $215,000. 83.67% of the stock is owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.